WO2007086013A1 - Préparation à base de ceftazidime, de tazobactam et de linézolide - Google Patents

Préparation à base de ceftazidime, de tazobactam et de linézolide Download PDF

Info

Publication number
WO2007086013A1
WO2007086013A1 PCT/IB2007/050245 IB2007050245W WO2007086013A1 WO 2007086013 A1 WO2007086013 A1 WO 2007086013A1 IB 2007050245 W IB2007050245 W IB 2007050245W WO 2007086013 A1 WO2007086013 A1 WO 2007086013A1
Authority
WO
WIPO (PCT)
Prior art keywords
ceftazidime
pharmaceutical composition
tazobactum
enhance
antimicrobial activity
Prior art date
Application number
PCT/IB2007/050245
Other languages
English (en)
Inventor
Jegannathan Srinivas
Original Assignee
Jegannathan Srinivas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jegannathan Srinivas filed Critical Jegannathan Srinivas
Publication of WO2007086013A1 publication Critical patent/WO2007086013A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention belongs to the field of pharmaceutical technology. More particularly the invention principally relates to a pharmaceutical composition in Injectable dosage form, comprising Ceftazidime its or pharmaceutically acceptable hydrates, salts or esters as the active ingredient, Tazobactum and further fortified with Linezolid, an Oxazolidinone.
  • Betalactamases which hydrolyze Betalactam antibiotics such as penicillins, cephalosporins and carbapenems. These enzymes catalyze the hydrolysis of the Betalactam ring to effectively destroy the antibiotic's activity.
  • Enzyme Inhibitors such as Tazobactum have been proved to be extremely useful in overcoming the bacterial resistance by inhibiting the betalactamase enzyme.
  • the enzyme inhibitors have a limited or nil action against the bacteria that produce Extended Spectrum Betalactamases (ESBL) such as Pseudomonas spp. Nevertheless, combining
  • Tazobactum has been found to substantially enhance the antibacterial activity even between second-generation cephalosporins, such as Cefaclor and Cefprozil (U.S. Patent Application No. 20030109503 of GSK).
  • Ceftazidime has an excellent activity against a wide range of Gram +ve and Gram -ve organisms. However, E.faecalis and Bacteroides are resistant to Ceftazidime. The Fixed Dose Combination with Linezolid provides this additional spectrum to make the composition suitable for empiric therapy, especially in critical conditions
  • Ceftazidime exhibits excellent activity against Gram -ve, aerobes and anaerobes including aeruginosa, but it has weaker activity against Gram +ve organism including aureus. Ceftazidime has minimal activity against MRSA. However, improved activity against MRSA can be demonstrated when combined with Vancomycin, Quinupristin-Dalfopristin and Linezolid (Allen et al, 2002, Vanthitha et al, 2005).
  • the objective of the present invention is to provide a pharmaceutical composition that provides Ceftazidime with an enhanced activity in combination with Tazobactum.
  • Another objective of the present invention is to provide a pharmaceutical composition that provides additional spectrum of activity with the addition of Linezolid, an Oxazolidinone, a new class of antibacterial with excellent activity against MRSA/VRSA and some anerobes
  • composition of this invention is in the Injectable dosage form comprising the active ingredients in fixed dose combination in specific ratios, with Arginine and Sodium citrate, etc., as inactive ingredients
  • the Ceftazidime, or its pharmaceutically acceptable hydrates, salts or esters may be present in an amount from 500 mg to 2000 mg.
  • cephalosporin antibiotics examples include all other I Generation Cephalosporins and, pharmaceutically acceptable hydrates, salts or esters thereof.
  • the Tazobactum is used in combination with Ceftazidime in a ratio of 1 :2, 1 :4 or 1 :8 based on the requirement for enhanced antimicrobial activity.
  • Tazobactum exhibits inhibitory action against Group 1 Cephalosporinases, Group 2br TEM Betalactamases and Group 3 Metallo Betalactamases
  • the pharmaceutical composition of the present invention may be prepared by procedures well known to formulation chemists.
  • the method of manufacturing can affect the release characteristics of the composition. The method is as follows:
  • This invention relates to pharmaceutical formulations, in particular to novel formulations for the treatment of bacterial infections.
  • Tazobactum in the form of its derivatives, particularly its salts, are consequently used in formulations in combination with antibiotics to suppress the activity of beta. -lactamase enzymes which mediate bacterial resistance to betalactam antibiotics.
  • Tazobactum exhibits inhibitory action against Group 1 Cephalosporinases, Group 2br TEM Betalactamases and Group 3 Metallo Betalactamases
  • This type of microorganisms includes penicillin- resistant organisms such as Streptococcus spp., e.g.
  • Tazobactum together with betalactam antibiotics is believed to be novel per se, and therefore in a further aspect of this invention there is provided a pharmaceutical formulation comprising in combination Tazobactum together with a cephalosporin antibiotic selected from the cephalosporins, Ceftazidime.
  • a cephalosporin antibiotic selected from the cephalosporins, Ceftazidime.
  • the betalactam antibiotics referred to herein may be in the form of the free acids or pharmaceutically acceptable salts or in-vivo hydrolysable esters.
  • Tazobactum and any other antibacterial agent such as the penicillin or cephalosporin antibiotics, as used in this invention, whether in the form of the free acids, salts, esters or derivatives thereof are preferably each in a substantially pure form, e.g. at least 60% pure, more suitably at least 75% pure, preferably at least 85% especially at least 98% pure on a weight basis.
  • the formulation may be formulated for administration by any route, such as oral, topical or parenteral.
  • the route of choice may for example be determined by the route of choice for the antibacterial agent used in combination with the Tazobactum.
  • the formulation may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present at from about 1 % up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • compatible conventional carriers such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • Such carriers may be present at from about 1 % up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate, talc, polyethylene glycol or silica
  • Such tablets may also include an effervescent couple of generally known type, e.g a solid carboxylic acid and an alkali metal carbonate or bicarbonate.
  • Such tablets may also include a chewable base such as mannitol, sorbitol or lactose, optionally together with an effervescent couple.
  • Such tablets and solid dosage forms may be made by any of the generally known methods for such dosage forms, and may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non- aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate,
  • Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing Tazobactum and any antibacterial agent and a sterile vehicle, water being preferred.
  • These active compounds depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the active compounds can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the formulation can be frozen after filling into the vial and the water removed under vacuum.
  • the dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the ingredients of the suspension are suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the formulation can be sterilised by exposure of its dry constituents to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the formulation to facilitate uniform distribution of the active compounds.
  • Aqueous solution and suspension formulations of this invention can only be provided in the form of dry solids for make up into aqueous solution or suspension shortly prior to use, for example 5 days in the case of oral suspensions. It may also be necessary to maintain such suspensions at low temperatures, e.g >5. degree. C.
  • a formulation according to the invention may be in unit dosage form, for example unit dosage form for oral or parenteral administration, which latter will primarily include administration by injection or infusion, especially intramuscular and intravenous administration.
  • the above-mentioned formulations may contain 0.1- 90% by weight, preferably from 10-60% by weight of the active materials, depending on the method of administration.
  • the Tazobactum may suitably be administered to the patient at a daily dosage ranging from 125 to 250 mg, preferably from 50 to 500 mg, of clavulanate expressed as its free acid equivalent may be administered daily, suitably in from 1 :8, preferably from 2:1 , separate doses. Higher or lower dosages may, however, be used in accordance with clinical practice.
  • Suitable unit dosages and maximum daily dosages of any antibacterial agent used in combination with Tazobactum in this invention may for example be determined according to the unit dosages and maximum daily dosages of the agent used conventionally.
  • Ceftazidime is generally provided in unit dosages of 500 and 2000 mg, and may be dosed up to a maximum daily dosage of 12000 mg per day.
  • Tazobactum with Ceftazidime in a ratio Tazobactum:Ceftazidime in the range 1 :4 to 1 :8, for example together in a formulation.
  • Ceftazidime is preferred as an Empiric therapy in Critical conditions and hence addition of Tazobactum and Linezolid would certainly give a new lease of life for this excellent antibiotic.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique de céftazidime et de tazobactum combinés en une dose fixe et de linézolide sous forme de dose injectable. Le tazobactum de la composition agit comme un inhibiteur enzymatique qui accentue l'activité antibactérienne du céptazidime en inhibant des bêtalactamases tels que les céphalosporinases, groupe 1, des TEM-bêtalactamases, groupe 2br et les métallo-bêtalactamases, groupe 3. Les principes actifs sont constitués fondamentalement par des antibiotiques bêtalactames pris dans le ceftazidime et du tazobactum en association avec un autre médicament, le linezolide, un oxazilidone faisant partie d'une nouvelle classe d'antibactériens exceptionnellement efficace scontre MRSA, VRSA, E-faecalis et les bactéroïdes, alors que le ceftazidime présente une activité plus faible. La composition de la présente invention pourrait jouer un rôle utile dans des cas critiques comme une thérapie empirique.
PCT/IB2007/050245 2006-01-25 2007-01-24 Préparation à base de ceftazidime, de tazobactam et de linézolide WO2007086013A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN122/CHE/2006 2006-01-25
IN122CH2006 2006-01-25

Publications (1)

Publication Number Publication Date
WO2007086013A1 true WO2007086013A1 (fr) 2007-08-02

Family

ID=38308902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/050245 WO2007086013A1 (fr) 2006-01-25 2007-01-24 Préparation à base de ceftazidime, de tazobactam et de linézolide

Country Status (1)

Country Link
WO (1) WO2007086013A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102875576A (zh) * 2012-10-31 2013-01-16 苏州致君万庆药业有限公司 一种抗菌素头孢他啶的合成、注射用头孢他啶及其制备方法
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US8968753B2 (en) 2013-03-15 2015-03-03 Calixa Therapeutics, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9044485B2 (en) 2013-03-15 2015-06-02 Calixa Therapeutics, Inc. Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034128A2 (fr) * 1999-11-08 2001-05-17 Pharmacia & Upjohn Company Melange de linezolid et d'autres agents antibacteriens
US20020022610A1 (en) * 2000-06-30 2002-02-21 Batts Donald H. Compositions and methods for treating bacterial infections
CN1452968A (zh) * 2002-04-23 2003-11-05 童明庆 新型的抗耐药菌的药物组合物及其制法和用途
WO2006064516A1 (fr) * 2004-12-17 2006-06-22 Venus Remedies Limited Associations d'antibiotiques pour fournir une solution totale au traitement des infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034128A2 (fr) * 1999-11-08 2001-05-17 Pharmacia & Upjohn Company Melange de linezolid et d'autres agents antibacteriens
US20020022610A1 (en) * 2000-06-30 2002-02-21 Batts Donald H. Compositions and methods for treating bacterial infections
CN1452968A (zh) * 2002-04-23 2003-11-05 童明庆 新型的抗耐药菌的药物组合物及其制法和用途
WO2006064516A1 (fr) * 2004-12-17 2006-06-22 Venus Remedies Limited Associations d'antibiotiques pour fournir une solution totale au traitement des infections

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN102875576A (zh) * 2012-10-31 2013-01-16 苏州致君万庆药业有限公司 一种抗菌素头孢他啶的合成、注射用头孢他啶及其制备方法
US8968753B2 (en) 2013-03-15 2015-03-03 Calixa Therapeutics, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9044485B2 (en) 2013-03-15 2015-06-02 Calixa Therapeutics, Inc. Ceftolozane antibiotic compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9925196B2 (en) 2013-03-15 2018-03-27 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
US10420841B2 (en) 2013-03-15 2019-09-24 Merck, Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US11278622B2 (en) 2013-03-15 2022-03-22 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US10933053B2 (en) 2013-09-09 2021-03-02 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane

Similar Documents

Publication Publication Date Title
WO2007086011A1 (fr) Composition à base de céfépime, de tazobactam et de linézolide
KR101738210B1 (ko) 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
EP1841432B1 (fr) Compositions destinees a lutter contre la resistance aux antibiotiques induite par la beta-lactamase au moyen des inhibiteurs de la beta-lactamase utiles pour injection
WO2007086013A1 (fr) Préparation à base de ceftazidime, de tazobactam et de linézolide
US20090275552A1 (en) Therapy for Treating Resistant Bacterial Infections
WO2007086014A1 (fr) Préparation à base de céfpirome, de tazobactam et de linézolide
EP0680322B1 (fr) Utilisation de clavulanate et un antibiotique pour le traitement d'infections
JP5961177B2 (ja) 化合物及びその使用
JP2018513188A (ja) 細菌感染症の処置方法
WO2007086012A1 (fr) Préparation de cefpodoxime, d'acide clavulanique et de linezolide
US6221859B1 (en) Carbapenem antibacterial compositions and methods of the treatment
CN113194943B (zh) 一种具有稳定性和抑菌活性的含有头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物
US20030109503A1 (en) Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
EP3565551B1 (fr) Méthodes de traitement d'infections bactériennes avec une combinaison de vaborbactam et meropenem
EP0384410B1 (fr) Composition anti-microbienne
CA1068603A (fr) Preparations contenant de la phosphonomycine et un autre antibiotique
MIYAUCHI et al. A novel oral carbapenem CS-834: Chemical stability of pivaloyloxymethyl esters of carbapenems and cephalosporins in phosphate buffer solution

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 23.12.2008.

122 Ep: pct application non-entry in european phase

Ref document number: 07700684

Country of ref document: EP

Kind code of ref document: A1